Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.60 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638929 | 1.00 | CNR2 (0.60) | CNR2CNR1TP53GAASMN1; SMN2 | |
| SCHEMBL19638882 | 0.85 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL29388451 | 0.85 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL29387398 | 0.81 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL19638844 | 0.81 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL29388385 | 0.76 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL19638754 | 0.76 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL29388664 | 0.75 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL10654147 | 0.72 | PGR (0.55) | CNR2CNR1LMNA | |
| SCHEMBL6013329 | 0.71 | KDM4E (0.59) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | PIKE THERAPEUTICS INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | PIKE THERAPEUTICS INC (CA) | 2025-08-07 | — | — | US | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| EP-4326252-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2024-02-28 | — | — | EP | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| CN-117545478-A | Transdermal pharmaceutical preparation for treating chronic pain | 长矛治疗股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117460503-A | Transdermal delivery of cannabidiol | 长矛治疗股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2024018420-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2024-01-25 | — | — | WO | disclosed |
| CN-117337174-A | Transdermal pharmaceutical formulation comprising CBD or THC for the treatment of cancer | 长矛治疗股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-116075296-A | Transdermal pharmaceutical preparation for treating multiple sclerosis | 长矛治疗股份有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916184-A | Transdermal and/or topical pharmaceutical formulations for the treatment of chronic pain comprising cannabidiol and/or tetrahydrocannabinol | 长矛治疗股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115884761-A | Transdermal pharmaceutical formulations of cannabinoids | 长矛治疗股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022224184-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS, INC. (CA) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| EP-4045024-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics, Inc., 1219014 B.C. Ltd. (CA) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022118303-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS, INC. (CA) | 2022-06-09 | — | — | WO | disclosed |
| CN-114555068-A | Transdermal administration of cannabidiol | 长矛治疗股份有限公司1219014 B.C.有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885TP53 4140/4885 |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | SOST, CNR2, BHMT2 | CNR2 2/4885CNR1 25/4885TP53 4690/4885 |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885TP53 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.